These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 20534267)

  • 1. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience.
    Perrella A; Esposito C; Ioia G; Campanella L; Taglialatela D; Cuomo O
    Transplant Proc; 2010 May; 42(4):1226-8. PubMed ID: 20534267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
    Fricke L; Steinhoff J; Hartwig-Weber I; Bein G
    Dtsch Med Wochenschr; 1997 May; 122(18):565-71. PubMed ID: 9190308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of donor-recipient cytomegalovirus serology on adult liver transplantation: a single center experience.
    Tryphonopoulos P; Weppler D; Morris MI; Russo C; Nishida S; Levi DM; Moon J; Tekin A; Selvaggi G; Island E; Arosemena L; Ruiz P; Tzakis AG
    Transplantation; 2011 Nov; 92(9):1051-7. PubMed ID: 21876474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors for cytomegalovirus infection after orthotopic liver transplantation using an ultrasensitive polymerase chain reaction assay.
    Basse G; Esposito L; Mengelle C; Kamar N; Ribes D; Lavayssière L; Pillet A; Suc B; Barange K; Rostaing L
    Transplant Proc; 2006 Sep; 38(7):2339-41. PubMed ID: 16980084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMV hepatitis after liver transplantation: incidence, clinical course, and long-term follow-up.
    Seehofer D; Rayes N; Tullius SG; Schmidt CA; Neumann UP; Radke C; Settmacher U; Müller AR; Steinmüller T; Neuhaus P
    Liver Transpl; 2002 Dec; 8(12):1138-46. PubMed ID: 12474153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gancyclovir prophylaxis in high risk patients.
    Campino A
    Transplant Proc; 2005 Dec; 37(10):4311-2. PubMed ID: 16387106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
    N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus infection in kidney transplant recipients: Evolution of approach through three eras.
    Boucher A; Lord H; Collette S; Morin M; Dandavino R
    Transplant Proc; 2006 Dec; 38(10):3506-8. PubMed ID: 17175316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
    Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
    Peggs KS; Preiser W; Kottaridis PD; McKeag N; Brink NS; Tedder RS; Goldstone AH; Linch DC; Mackinnon S
    Br J Haematol; 2000 Dec; 111(3):782-90. PubMed ID: 11122138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients.
    Hoppe L; Marroni CA; Bressane R; Lago L; Schiavo FL; Cigerza GC; Brandão AB; Zanotelli ML; Cantisani GP
    Transplant Proc; 2006; 38(6):1922-3. PubMed ID: 16908324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of pre-emptive therapy for cytomegalovirus after liver transplantation.
    Müller V; Perrakis A; Meyer J; Förtsch T; Korn K; Croner RS; Yedibela S; Hohenberger W; Schellerer VS
    Transplant Proc; 2012 Jun; 44(5):1357-61. PubMed ID: 22664015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus infection and disease following renal transplantation: preliminary report of incidence and potential risk factors.
    Taherimahmoudi M; Ahmadi H; Baradaran N; Montaser-Kouhsari L; Salem S; Mehrsai A; Kalantar E; Jahani Y; Pourmand G
    Transplant Proc; 2009 Sep; 41(7):2841-4. PubMed ID: 19765452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients.
    Casillo R; Grimaldi M; Ragone E; Maiello C; Marra C; De Santo L; Amarelli C; Romano G; Della Corte A; Portella G; Tripodi MF; Fortunato R; Cotrufo M; Utili R
    Transplant Proc; 2004 Apr; 36(3):651-3. PubMed ID: 15110622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.